CAMPAS C; CASTANER R: "AVE-0010 GLP-1 Receptor Agonist Treatment of Diabetes" DRUGS OF THE FUTURE, vol. 33, no. 10, October 2008 (2008-10), pages 838-840, XP002572655 ISSN: 0377-8282 (B1)

CHRISTENSEN M; KNOP F K; HOLST J J; VILSBOLL T: "Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus." IDRUGS : THE INVESTIGATIONAL DRUGS JOURNAL AUG 2009, vol. 12, no. 8, August 2009 (2009-08), pages 503-513, XP002572656 ISSN: 2040-3410 (B1)

ROSENSTOCK J; RATNER R E; BOKA G: "Dose range effects of the new once daily GLP-1 receptor agonist AVE0010 added to metformin in type 2 diabetes" DIABETOLOGIA, vol. 51, no. Suppl. 1, September 2008 (2008-09), page S66, XP009130805 44TH ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-DIAB ETES; ROME, ITALY; SEPTEMBER 08 -11, 2008 ISSN: 0012-186X (B1)

RATNER R E; ROSENSTOCK J; BOKA G: "A dose-finding study of the new GLP-1 agonist AVE0010 in type 2 diabetes insufficiently controlled with metformin" DIABETES, vol. 57, no. Suppl. 1, June 2008 (2008-06) , page A129, XP009130802 68TH ANNUAL MEETING OF THE AMERICAN-DIABETES-ASSOCIATION; SAN FRANCISCO, CA, USA; JUNE 06 -10, 2008 ISSN: 0012-1797 (B1)

Gabriel S: "New Diabetes Compound AVE0010 Showed Clear Dose Response Results with one-a-Day Injection in Phase IIb Study" Press release Sanofi-aventis, ADA Annual Scientific Sessions 7 June 2008 (2008-06-07), pages 1-2, XP002572653 Retrieved from the Internet: URL:http://www.zealandpharma.com/pdf/Press -release-June-2008-Phase-II-data-on-AVE001 0.pdf> [retrieved on 2010-03-11] (B1)